Poolbeg Pharma has partnered with a Nasdaq-listed biopharma company on its oral delivery platform.
The strategic collaboration will see both companies develop an optimised oral drug to treat a metabolic condition.
Poolbeg said that it will receive funding to work with its new partner to produce a prototype drug. This drug will utilise Poolbeg’s licensed oral delivery technology. It has an exclusive licence on patented oral delivery technologies for all metabolic conditions.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.